abbvie
On June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults with moderate to severe ulcerative colitis. This approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis, and Crohn’s disease. Supported by robust data from two Phase 3 clinical trials, INSPIRE and COMMAND, the approval highlights Skyrizi’s potential to become a cornerstone therapy in AbbVie’s portfolio, particularly as a s...
Invezz
16 Stocks For 2021, by Dr. David Kass Q3 2020 hedge fund letters, conferences and more Our expert’s picks have outperformed. Here are his latest. SMITH BRAIN TRUST – Maryland Smith’s David Kass has made his list and checked it twice. And he’s adding a few new stocks to his expanded semi-annual “nice” list of 16 stocks to watch for 2021. Once again, his midyear picks did very well, returning +30% (before dividends) over the latter six months of 2020, compared to the Dow Jones Industrial Average’s approximate return of +16% and S&P 500’s +18%. The best performers in Kass’ portfolio were upscale ...
ValueWalk
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら